Hjem › Schizofreni › Illinois
Kliniske studier for Schizofreni i Illinois
26 studier for Schizofreni søker deltakere på steder i Illinois.
Byer i Illinois
Offisiell studietekst (engelsk)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 59 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
RekruttererFase 1
Alder 18 til 55 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
RekruttererFase 3
Alder 5 til 17 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RekruttererFase 3
Alder 5 til 17 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
RekruttererFase 2
Alder 18 til 55 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
RekruttererFase 3
Alder 13 til 17 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
RekruttererFase 1
Alder 18 til 55 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
RekruttererFase 3
Alder 10 til 17 · Alle kjønn · Oppdatert 14. aug. 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
RekruttererObservasjonsstudie
Alder 18 til 40 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
RekruttererFase 2
Alder 18 til 55 · Alle kjønn · Oppdatert 23. jun. 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
RekruttererFase 4
Alder 18 til 65 · Alle kjønn · Oppdatert 3. jun. 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
RekruttererFase 4
Alder 18 til 60 · Alle kjønn · Oppdatert 11. mai 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
RekruttererObservasjonsstudie
Alder 18 til 40 · Alle kjønn · Oppdatert 10. mar. 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 6. mar. 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
RekruttererFase 3
Alder 18 til 65 · Alle kjønn · Oppdatert 12. jan. 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
RekruttererFase 2
Alder 21 til 55 · Alle kjønn · Oppdatert 26. des. 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
Alder 18 til 65 · Alle kjønn · Oppdatert 19. des. 2024 · NCT05184335Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.